Kidney Cancer Updates

Restricted access

News concerning combination drugs in the kidney cancer space continues apace. Recently, Merck & Co. and Pfizer obtained approval from the US Food and Drug Administration (FDA) for a combination of Merck’s Keytruda (pembrolizumab) and Pfizer’s Inlyta (axitinib) as a frontline treatment for patients with advanced renal cell carcinoma.

OncLive reported that the findings from the phase 3 KEYNOTE-426 trial showed that the frontline combination significantly improved overall response rates (ORRs), as well as progression-free and overall survival compared with Pfizer’s Sutent (sunitinib), a tyrosine kinase inhibitor. The data showed that the combination reduced the risk of death by 47%